Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.

Jonathan C. Song; Peter J. McDonnell; Erlinda M. Gordon; Frederick L. Hall; W. French Anderson

Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.

Jonathan C. Song, Peter J. McDonnell, Erlinda M. Gordon, Frederick L. Hall, W. French Anderson

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	306-309
Number of pages	4
Journal	Human gene therapy
Volume	14
Issue number	3
State	Published - Feb 10 2003

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Genetics

Cite this

Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring. / Song, Jonathan C.; McDonnell, Peter J.; Gordon, Erlinda M. et al.

In: Human gene therapy, Vol. 14, No. 3, 10.02.2003, p. 306-309.

Research output: Contribution to journal › Article › peer-review

@article{fd163d9c6093460eb2db7f12610626a9,

title = "Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.",

author = "Song, {Jonathan C.} and McDonnell, {Peter J.} and Gordon, {Erlinda M.} and Hall, {Frederick L.} and Anderson, {W. French}",

note = "Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "2003",

month = feb,

day = "10",

language = "English (US)",

volume = "14",

pages = "306--309",

journal = "Human Gene Therapy",

issn = "1043-0342",

publisher = "Mary Ann Liebert Inc.",

number = "3",

}

TY - JOUR

T1 - Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.

AU - Song, Jonathan C.

AU - McDonnell, Peter J.

AU - Gordon, Erlinda M.

AU - Hall, Frederick L.

AU - Anderson, W. French

N1 - Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

PY - 2003/2/10

Y1 - 2003/2/10

UR - http://www.scopus.com/inward/record.url?scp=0141560775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141560775&partnerID=8YFLogxK

M3 - Article

C2 - 12675032

AN - SCOPUS:0141560775

SN - 1043-0342

VL - 14

SP - 306

EP - 309

JO - Human Gene Therapy

JF - Human Gene Therapy

IS - 3

ER -

Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.

ASJC Scopus subject areas

Other files and links

Cite this